Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: IAM1363 in HER2 Cancers Primary completion pushed from Dec 2027 to Oct 2028 Iambic Therapeutics, IncPhase 1/2 NCT06253871
  2. Notable: Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection Primary completion pushed from Nov 2026 to Mar 2029 Vir Biotechnology, Inc.Phase 2 NCT07142811
  3. Notable: SFL-0821 · FSHD Primary and study completion dates pushed to Aug 2029 Soufflé Therapeutics, Inc.Phase 1/2 NCT07798609
  4. Notable: GC310 Injection · Wilson's Disease (WD) Primary completion pushed from Apr 2027 to Dec 2027 GeneCradle IncPhase 1/2 NCT07173933
  5. Notable: HALOS · ION582 · Angelman Syndrome Primary and study completion pushed from Mar 2029 to Mar 2032 Ionis Pharmaceuticals, Inc.Phase 1/2 NCT05127226
  6. Notable: KITE-363 · Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment Primary and study completion pushed from Jun 2029 to Dec 2031 Kite, A Gilead CompanyPhase 1 NCT07304154
  7. Notable: Using the 'Pivot Extend' System as a Treatment · Tricuspid Regurgitation Primary completion pushed from Apr 2026 to Nov 30, 2027 Tau Medical Australia Pty LtdNot applicable NCT07172477
  8. Notable: DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity Primary completion pushed from Jun 5, 2026 to Dec 5, 2027 José Antonio Mata MarínPhase 3 NCT07075146
  9. Notable: Syde® Digital Endpoints for Monitoring · Progressive Supranuclear Palsy - Richardson Syndrome (PSP-R) Primary and study completion pushed from Mar 2028 to Nov 2028 SYSNAVNot specified NCT07389018
  10. Notable: Royal Ancient Oats™ Study Primary completion pushed from Jun 30, 2026 to Jun 30, 2027 Standard Process Inc.Not applicable NCT07371598
  11. Notable: Stryker Facial iD Universal Plate Configurator: A Retrospective Post Market Follow Up Primary and study completion pushed from May 31, 2026 to Mar 30, 2027 Stryker CraniomaxillofacialNot specified NCT07245810
  12. Notable: Binimetinib · BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer Primary completion pushed from Feb 28, 2027 to Feb 28, 2028 National Cancer Center, JapanPhase 2 NCT06159478
  13. Notable: Delivery Outcomes by AIDA (Artificial Intelligence Dystocia Algorithm) Analysis Primary completion pushed from Dec 30, 2025 to Aug 30, 2027 Centro di Ricerca Clinica SalentinoNot specified NCT06664112
  14. Notable: Muscle Response to Different Amounts of Dietary Protein During Leg Immobilization Primary and study completion pushed from Sep 2026 to Apr 2027 United States Army Research Institute of Environmental MedicineNot applicable NCT07069426
  15. Notable: Treatment Costs of Kidney Injury in Patients Having Heart Surgery in the UK Primary and study completion pushed from Apr 1, 2027 to Dec 1, 2027 The Royal Wolverhampton Hospitals NHS TrustNot specified NCT07719569
  16. Notable: Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood · Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Primary and study completion pushed from Dec 31, 2030 to Dec 31, 2032 PedAL BCU, LLCPhase 1/2 NCT04726241
  17. Notable: Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) Primary completion pushed from May 2025 to May 2027 Vall d'Hebron Institute of OncologyPhase 2 NCT03767075
  18. Notable: Ixazomib Maintenance Study · AL Amyloidosis Primary and study completion pushed from Aug 2026 to Aug 2027 Memorial Sloan Kettering Cancer CenterPhase 2 NCT03618537
  19. Notable: Mitapivat Sulfate · Erythrocyte Membranopathies Primary completion pushed from Jul 15, 2025 to Sep 30, 2028 EuroBloodNet AssociationPhase 2 NCT05935202
  20. Notable: Hybrid Robot+FES Stroke Rehabilitation Primary completion pushed from Oct 1, 2026 to Oct 1, 2027 University of Maryland, BaltimorePhase 1/2 NCT04550728
  21. Notable: BCAA vs. Rifaximin · Cirrhosis for Secondary Prophylaxis of HE Primary completion pushed from Aug 2026 to Aug 2027 Post Graduate Institute of Medical Education and Research, ChandigarhPhase 4 NCT06538077
  22. Notable: Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma Primary completion pushed from Jul 1, 2028 to Jul 1, 2030 National Cheng-Kung University HospitalPhase 2 NCT06903273
  23. Notable: Active Surveillance and Chemotherapy Before Surgery · Stage II-III Rectal Cancer Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2028 M.D. Anderson Cancer CenterEarly Phase 1 NCT03594630
  24. Notable: HSV G207 · Recurrent or Refractory Cerebellar Brain Tumors Primary and study completion dates pushed to Dec 31, 2027 M.D. Anderson Cancer CenterPhase 1 NCT03911388
  25. Notable: Antimicrobial Effect of Tropolone Containing Versus Tropolone Free Mouthwash Primary completion pushed from Oct 2026 to Oct 2027 Cairo UniversityEarly Phase 1 NCT03384537